Centessa Pharmaceuticals plc
CNTA
$39.60
-$0.02-0.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.57% | -28.96% | -14.90% | 31.31% | -202.22% |
| Total Depreciation and Amortization | 2.97% | 0.42% | -4.24% | -9.58% | -462.75% |
| Total Amortization of Deferred Charges | 46.50% | -- | -- | -- | 316.67% |
| Total Other Non-Cash Items | -80.02% | -17.65% | 0.50% | -29.85% | 380.16% |
| Change in Net Operating Assets | -95.15% | -193.60% | 413.88% | -319.24% | 831.86% |
| Cash from Operations | -30.39% | -172.63% | 44.67% | -53.53% | -37.84% |
| Capital Expenditure | -- | -588.24% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -972.49% | 38.18% | 28.18% | -1,426.74% | 237.01% |
| Cash from Investing | -972.54% | 37.77% | 27.96% | -1,426.74% | 236.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5,238.50% | -98.56% | -98.42% | -24.98% | -16.49% |
| Repurchase of Common Stock | 88.91% | 87.11% | -62.62% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9,464.63% | -98.60% | -98.48% | -70.59% | -53.42% |
| Foreign Exchange rate Adjustments | -44.49% | 73.69% | 5.83% | -792.69% | 701.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 194.38% | -97.55% | -765.44% | -2,733.93% | 72.84% |